Literature DB >> 9489600

Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin.

J H Soul-Lawton1, B C Weatherley, J Posner, G Layton, R W Peck.   

Abstract

AIMS: Changes in both digoxin and aciclovir renal clearance following coadministration with some other renally eliminated drugs have been reported. The potential interaction of valaciclovir, with its antiherpetic metabolite aciclovir, and digoxin was investigated.
METHODS: Twelve healthy volunteers (seven males, five females) participated in an open, randomized, four-period crossover study. Valaciclovir, 1000 mg, was given alone on one occasion, and on another, after the second of two 0.75 mg digoxin doses administered 12 h apart. Blood samples and all urine were collected up to 12 h following the valaciclovir dose for aciclovir radioimmunoassay. On a third occasion, digoxin was given alone and on a fourth, with 1000 mg valaciclovir three times/day for 8 days starting 12 h before the first digoxin dose. Blood samples were taken up to 168 h and all urine collected up to 24 h following the second dose for digoxin radioimmunoassay.
RESULTS: There were no clinically significant differences in digoxin or aciclovir pharmacokinetic parameters when digoxin or valaciclovir was given alone or in combination.
CONCLUSIONS: No dosage adjustment is required when valaciclovir and digoxin are coadministered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489600      PMCID: PMC1873995          DOI: 10.1046/j.1365-2125.1998.00649.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

Review 1.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 2.  Clinical pharmacokinetic significance of the renal tubular secretion of digoxin.

Authors:  G Koren
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of digoxin 1980.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

4.  A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine].

Authors:  R P Quinn; P de Miranda; L Gerald; S S Good
Journal:  Anal Biochem       Date:  1979-10-01       Impact factor: 3.365

5.  Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans.

Authors:  O L Laskin; P de Miranda; D H King; D A Page; J A Longstreth; L Rocco; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

6.  Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.

Authors:  J Soul-Lawton; E Seaber; N On; R Wootton; P Rolan; J Posner
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

  6 in total
  1 in total

Review 1.  Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.

Authors:  C M Perry; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.